Eli Lilly’s Experimental Drug Retatrutide Cuts Knee Osteoarthritis Pain in Phase 3 Obesity Trials

A weekly weight-loss shot may soon do double duty for aching joints.

Researchers across the United States, Canada, Australia, and the United Kingdom found that retatrutide—an experimental drug developed by Eli Lilly—markedly eases knee osteoarthritis pain in adults living with obesity. The findings, published in the New England Journal of Medicine, push GLP-1 class medications well beyond simple appetite control and into the realm of direct orthopedic therapy.

For decades, doctors handed patients with joint decay a frustrating mandate: lose weight first, or live with the pain. Excess body mass hammers knees with every stride, grinding down cartilage and feeding chronic inflammation. Yet exercising with worn-out joints often feels impossible. The trial data offers a physical escape hatch from that trap.

The findings emerged from two rigorous Phase 3 clinical trials testing once-weekly subcutaneous injections. The study focused strictly on individuals who carried a body mass index (BMI) of at least 27 alongside chronic knee osteoarthritis, while excluding patients with diabetes to isolate the joint and weight outcomes.

Retatrutide remains experimental and awaits full regulatory evaluation before it can reach pharmacy shelves. Anyone struggling with degenerative joint pain should speak directly with an orthopedic specialist or physician before altering existing pain management routines.